Consulting for biotech and pharma

Commercial strategy and patient-services analytics

We help drug developers choose indications, forecast sales and evaluate licensing offers. We work with patient-support teams to find delays on the way to treatment and flag the cases staff need to follow up.

Our experience

Our work before Next Indication includes patient-based forecasts for more than ten oncology assets and recurring case reports for patient-support teams.

Commercial strategy and forecasting

Indication selection

The largest disease population doesn’t always offer the best opportunity for a drug. We look at who would qualify for treatment in each indication, what those patients receive today and which competitors could reach the market first. We recommend which indication to pursue and explain what would change our view.

Patient-based forecasts

We build the forecast from the patients who could actually receive the drug. For a biomarker-defined therapy, that means knowing how many patients reach the treatment line, get tested, qualify and have coverage. We then estimate how prescribing is split among competing treatments and what the manufacturer receives per course. You can use the workbook to test a coverage restriction before launch or a change in price and prescribing after exclusivity ends.

Forecast review

If two forecasts disagree, we work through them to find out why. Often the difference starts with who gets counted or how quickly a team expects prescribing to change. We can also review a single model, check the calculations and document any corrections.

Valuation and licensing

We estimate the risk-adjusted value of an asset using expected sales, development costs, timing and probability of success. For licensing discussions, we model the value to each party. You can compare the upfront payment, milestones and royalties, test what happens if development takes longer or sales fall short, and use the same workbook when a counteroffer comes in.

Competitive intelligence

We follow the trials and treatments that compete with your asset. When results come out, we look at the patients enrolled, the comparator and where the drug could fit in practice. We explain whether the findings warrant a change to your forecast or development plans.

Launch forecast

What would narrower insurance coverage mean for sales?

Independent demonstration project, not a prior client engagement. All figures are illustrative.

Imagine you’re preparing a launch plan for a biomarker-defined oncology drug. In one market, 32,000 people are newly diagnosed each year. Assume 60% reach the intended line and receive drug treatment, three quarters of them get tested, and one in four tests positive. That gives you 3,600 patients a year who meet the modelled treatment and biomarker criteria.

How many would actually receive the brand? Suppose 80% can obtain coverage for it. Of those patients, half receive a drug from its class. If your brand wins 40% of prescriptions within that class at peak uptake, the forecast is 576 patients a year. At a net price of $140,000 per course, that’s about $81 million in annual sales.

Patients per year Hypothetical inputs

New diagnoses32,000
Drug-treated in target line19,200
Biomarker test available14,400
Biomarker-positive (eligible)3,600
Coverage for the brand2,880
Receive a drug in the class1,440
Receive the brand at full uptake576

Share of eligible patients who can obtain reimbursement for this brand.

Live result, Base case: 80% coverage, peak uptake in year 5, exclusivity through year 10

Eligible patients per year3,600
Brand share of eligible patients16%576 of 3,600 eligible
Realised net price per course$140,000
Peak annual net sales$80.6M
Year-12 net sales$38.7M
12-year cumulative net sales$741.9M

Competing products enter after year 10.

Population
Prescribing
Pricing
Exclusivity
Fixed comparison at peak uptake Fixed illustration at Base settings
Base coverageNarrower coverage
Eligible patients per year3,6003,600
Share with coverage for the brand80%60%
Patients receiving the brand per year576432
Peak annual net sales$80.6M$60.5M

In the narrower-coverage case, the biology and the competitive assumptions are identical. The coverage difference alone accounts for 144 fewer patients a year and about $20 million in sales. If those two cases lead to different launch plans, the first assumption to investigate is which eligible patients can obtain reimbursement.

You can also explore what happens after loss of exclusivity. In the base example, competing products enter after year 10. Over the next two years, the brand loses 40% of its patient volume and its net price falls 20%. Annual brand sales fall from $80.6 million in year 10 to $38.7 million in year 12. Change either assumption to see how much of the decline comes from prescribing and how much comes from price.

Model scope: one incident cohort per year, one course per treated patient and a constant market size. Sales are before costs, discounting and development risk.

Patient services and reporting

Patient journeys

If patients are taking longer than expected to get their first prescription filled, where are they waiting? We use the dates in your program and pharmacy records to trace each step, from enrolment and the insurance check to the first dispense. We show where time builds up and which missing records your team needs to check.

Case review and follow-up

We build a review list around the handoffs your staff manage. A coordinator can see when a case last moved, who owns the next step and whether someone has already followed up. The program lead can then see which cases progressed and which are still waiting.

Data engineering and reporting automation

For a report someone rebuilds every week, we start with the last run. We trace the source files, automate the repeat steps and build checks for missing records or changed definitions. The person taking over gets a working report and instructions for the next update.

Analytics product ownership

We work with the staff who will use a new tool, agree on what the first release needs to do and coordinate the build with the technical team. We test it on everyday tasks with users and agree on who will maintain it.

Patient journey

Where is the first prescription held up?

Independent demonstration project, not a prior client engagement. The cases and review thresholds are illustrative.

In this specialty-drug program, the prescriber sends a referral and the support team enrols the patient. A coordinator checks the patient’s insurance to see whether the drug is covered and whether the insurer needs prior authorisation. If it does, the prescriber supplies the requested information and the team tracks the insurer’s decision. Once the referral is ready, the support team sends it to the specialty pharmacy. The pharmacy confirms receipt, contacts the patient and records the first dispense.

  1. Referral received
  2. Patient enrolled
  3. Insurance check
    • APrior authorisation, when required. Documentation request open three business days. After approval the referral rejoins at Ready for pharmacy.
  4. BReady for pharmacy. Six business days with no record of pharmacy receipt.
  5. Referral sent
  6. CPharmacy confirmed receipt. Four business days with no first dispense recorded.
  7. Patient contacted
  8. First dispense recorded

A status of “pending” tells the program lead very little. Here’s what staff would see when they review three cases from that same program.

CaseLast recorded stepWhy it came up for reviewWho follows up and what they do
ACase A Insurance check complete Prior authorisation requires a clinical note. The request has been open for three business days. The coordinator asks the prescriber’s office for the note so the request can go to the insurer.
BCase B Ready for pharmacy Six business days have passed with no record that the pharmacy received the referral. The hub reviewer checks with the pharmacy. It already has the referral, so the reviewer updates the record and avoids sending a duplicate.
CCase C Pharmacy confirmed receipt Four business days later, the record shows no first dispense. The pharmacy liaison confirms that patient contact is already scheduled and records the next follow-up date.

Those cases call for different action. The program lead can use the list to see which referrals need help from a prescriber, which records need correcting and which cases already have someone following up.

Discuss a project

If you have a project in mind, email us with the question and any deadline you’re working toward.